UK cost agency endorses Novartis heart drug for some patients
LONDON (Reuters) - Novartis's big new drug hope Entresto has been recommended for use in some patients with heart failure by Britain's cost agency NICE, which said on Friday it believed the treatment was a cost-effective option.
Aucun commentaire:
Enregistrer un commentaire